Vaxxinity to Present at Upcoming Investor Conferences in September
DALLAS, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, a biotechnology company focused on immunotherapeutic vaccines, announces CEO Mei Mei Hu will present at two September investor conferences. The H.C. Wainwright 24th Annual Global Investment Conference is on September 12, 2022, from 10:00 a.m. to 10:30 a.m. ET. The Baird Global Healthcare Conference follows on September 13, 2022, from 3:10 p.m. to 3:40 p.m. ET. Both presentations will be available via webcast for 90 days. Vaxxinity aims to innovate in chronic disease treatment with peptide-based vaccines.
- None.
- None.
DALLAS, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that Mei Mei Hu, Chief Executive Officer of Vaxxinity, will present at the following investor conferences in September:
H.C. Wainwright 24th Annual Global Investment Conference
Date: Monday, September 12, 2022
Time: 10:00 a.m. – 10:30 a.m. (ET)
Presentation Format: Corporate Presentation
Baird Global Healthcare Conference
Date: Tuesday, September 13, 2022
Time: 3:10 p.m. – 3:40 p.m. (ET)
Presentation Format: Fireside Chat
A live webcast of the presentation and fireside chat can be accessed under “Events & Presentations” in the Investor section of the Company’s website, and will be available for replay for 90 days following each event. All presentation times are subject to change.
About Vaxxinity
Vaxxinity, Inc. is a purpose-driven biotechnology company committed to democratizing healthcare across the globe. The company is pioneering a new class of synthetic, peptide-based immunotherapeutic vaccines aimed at disrupting the existing treatment paradigm for chronic disease, increasingly dominated by monoclonal antibodies, which suffer from prohibitive costs and cumbersome administration. The company’s proprietary technology platform has enabled the innovation of novel pipeline candidates designed to bring the efficiency of vaccines to the treatment of chronic diseases, including Alzheimer’s, Parkinson’s, migraine, and hypercholesterolemia. The technology is also implemented as part of a COVID-19 vaccine program. Vaxxinity has optimized its pipeline to achieve a potentially historic, global impact on human health.
For more information about Vaxxinity, Inc., visit http://www.vaxxinity.com and follow us on social media @vaxxinity.
Forward-looking Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including "potentially," and "will" and similar expressions, are intended to identify forward-looking statements. These forward-looking statements involve substantial risks and uncertainties, and are based on the current expectations and assumptions of Vaxxinity’s management. Forward-looking statements include statements about the development of a new class of immunotherapeutic vaccines and the innovation and efficacy of Vaxxinity’s product candidates. Various important factors could cause actual results or events to differ materially from those that may be expressed or implied by our forward-looking statements. Additional important factors to be considered in connection with forward-looking statements are described in the "Risk Factors" section of the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 24, 2022 and other reports we file with the Securities and Exchange Commission. The forward-looking statements are made as of this date and Vaxxinity does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Investor Contact
Benjamin Matone
benm@vaxxinity.com
Press Contact
Karen Chase
media@vaxxinity.com
FAQ
What are the investor conferences Vaxxinity will be attending in September 2022?
What time will Mei Mei Hu present at the H.C. Wainwright conference?
How can I access the Vaxxinity presentations from the investor conferences?
What is the focus of Vaxxinity's immunotherapeutic vaccines?
How long will the webcasts of the Vaxxinity presentations be available?
